Alkem Laboratories Ltd
NSE:ALKEM
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4 521.15
6 366.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Alkem Laboratories Ltd
Alkem Laboratories Ltd
Operating Income
Alkem Laboratories Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alkem Laboratories Ltd
NSE:ALKEM
|
Operating Income
₹21.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Operating Income
₹65B
|
CAGR 3-Years
28%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Operating Income
₹56.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
21%
|
CAGR 10-Years
14%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Operating Income
₹112.5B
|
CAGR 3-Years
13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
4%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Operating Income
₹27.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Operating Income
₹21.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Alkem Laboratories Ltd
Glance View
Alkem Laboratories Ltd. is a prominent player in the pharmaceutical industry, rooted in its commitment to research, development, and manufacturing of high-quality generic medications. Founded in 1973 and headquartered in Mumbai, India, Alkem has successfully carved out a significant market share in both domestic and international markets. With a diverse product portfolio encompassing over 700 generics across various therapeutic categories, the company's innovative approach and stringent adherence to regulatory compliance have earned it a robust reputation. Alkem's strategic focus on expanding its presence in key global markets, particularly the United States, positions it well to capitalize on the growing demand for affordable healthcare solutions. As investors look for opportunities in the pharmaceutical sector, Alkem Laboratories stands out not just for its ambitious growth trajectory, but also for its proven track record of delivering consistent financial performance. The company's recent investments in state-of-the-art facilities and research initiatives underscore its dedication to innovation and efficiency. Furthermore, with a robust pipeline of products in various stages of development, Alkem is well-equipped to navigate the dynamic regulatory landscape and competitive pressures in the industry. For investors, the blend of Alkem's established market position, commitment to quality, and proactive expansion strategy signals a compelling opportunity backed by solid fundamentals.
See Also
What is Alkem Laboratories Ltd's Operating Income?
Operating Income
21.6B
INR
Based on the financial report for Jun 30, 2024, Alkem Laboratories Ltd's Operating Income amounts to 21.6B INR.
What is Alkem Laboratories Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
17%
Over the last year, the Operating Income growth was 45%. The average annual Operating Income growth rates for Alkem Laboratories Ltd have been 8% over the past three years , 17% over the past five years .
You don't have any saved screeners yet
